What is Demeetra?
Demeetra AgBio is at the forefront of life sciences innovation, specializing in advanced gene-editing technologies such as Cas-CLOVER and piggyBac® transposase. These tools are engineered to precisely modify traits in living organisms, supporting both commercial bioprocessing and fundamental discovery research. Demeetra's integrated genome engineering platforms are designed for flexibility, enabling clients to achieve exact genome edits and establish stable gene expression. The company serves a diverse clientele, including biotechnology firms, contract development and manufacturing organizations (CDMOs), and academic research institutions. By offering adaptable licensing agreements and comprehensive expert guidance throughout the product development lifecycle, Demeetra empowers its partners to expedite discovery timelines and scale production efficiently, while also ensuring freedom to operate within the complex biologics manufacturing landscape.
How much funding has Demeetra raised?
Demeetra has raised a total of $92K across 1 funding round:
Debt
$92K
Debt (2021): $92K with participation from PPP
What's next for Demeetra?
With the recent influx of substantial expansion capital, Demeetra is poised for a significant phase of growth. This strategic investment is expected to fuel further research and development into its gene-editing platforms, potentially expanding its application areas and enhancing its technological capabilities. The company is likely to focus on scaling its operations, increasing its market reach, and solidifying its position as a leader in the gene-editing technology space. Further strategic partnerships and commercialization efforts are anticipated as Demeetra leverages this funding to accelerate its mission of engineering traits for life.
See full Demeetra company page
